title: Infection and infection prevention in patients treated with immunosuppressive medications for autoimmune bullous disorders.
abstract: Infection contributes to considerable morbidity and mortality in patients treated for autoimmune bullous disorders because of the impaired cutaneous barrier, alteration of the protective normal flora, and host immunosuppression (inherent and iatrogenic). Prevention of cutaneous impetiginization and infection starts with excellent wound care. In patients to be started on immunosuppressive medications, consideration should be given to vaccination status and possible need for pneumocystis pneumonia prevention. Patients should be educated on the signs and symptoms of early infection and the need to seek early medical intervention as needed.
authors.affiliation: Department of Dermatology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
authors.forename: Julia S
authors.initials: JS
authors.lastname: Lehman
authors.forename: Dédée F
authors.initials: DF
authors.lastname: Murrell
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Camilleri
authors.forename: Amer N
authors.initials: AN
authors.lastname: Kalaaji
mesh_terms: D001327:Autoimmune Diseases / Q000188:drug therapy*; D001424:Bacterial Infections / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D009181:Mycoses / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control; D012872:Skin Diseases, Vesiculobullous / Q000188:drug therapy*; D016896:Treatment Outcome; D014777:Virus Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control
chemical_list: D007166:Immunosuppressive Agents